— Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a fourth-quarter 2019 loss of $0.78 per share versus a loss of $0.14 per share expected.
— Revenue remained flat at $29,000 versus $40,000 expected. The top line was hurt by nil contract revenue.
— The bottom line was hurt by an increase in the estimated fair value of derivative warrant liabilities.
— Research and development expenses increased by 23% due to costs related to NDA submission preparation costs, higher personnel costs, higher costs incurred for the Aurora 2 extension trial, and the Audrey DES phase 2/3 study.
— During the second half of 2020, the company anticipates reporting interim data from the exploratory Phase 2 FSGS study and results from the Phase 2/3 Audrey DES trial evaluating 3 concentrations of VOS compared to the vehicle alone.
— The company believes it has sufficient financial resources to fund its current plans. This includes ongoing R&D programs, completing the NDA submission, manufacturing and packaging commercial drug supply required for launch, and fund its supporting corporate and working capital needs through 2021.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
American Express (AXP) Q2 2025 Earnings: Key financials and quarterly highlights
American Express Company (NYSE: AXP) reported its second quarter 2025 earnings results today. Consolidated total revenues, net of interest expense, were $17.9 billion, up 9% year-over-year, driven by increased Card
Netflix Q2 earnings jump on strong revenue growth; results beat estimates
Video streaming giant Netflix, Inc. (NASDAQ: NFLX) reported a sharp increase in revenue and profit for the second quarter of fiscal 2025. The numbers also beat analysts' estimates. The company's
Tesla Q2 Earnings Preview: Can energy gains offset EV demand Slump?
For Tesla Inc. (NASDAQ: TSLA), the new fiscal year has been quite challenging, with first-quarter sales falling to a three-year low amid production issues related to Model Y and increasing
